SWOG clinical trial number
SWOG-9512 (E1694)

A Phase III Study of Adjuvant Ganglioside Vaccination GM2- KLM/QS-21 Therapy vs. High-Dose Interferon Alpha-2b (Intron A) for High Risk Melanoma (T4>4 mm Primary or Regional Lymph Node Metastasis)

Closed
Phase
Published
Abbreviated Title
Ganglioside Vaccination in Melanoma
Activated
07/15/1996
Closed
10/15/1999

Research committees

Melanoma

Publication Information Expand/Collapse

2002

Letter to the editor: Interferon alfa-2a for melanoma metastases

Jm Kirkwood;JG Ibrahim;VK Sondak;MS Ernstoff;M Ross The Lancet 359:978-979

In reply to the Letter to the Editor: Sentinel-node technique will change the design of clinical trials in malignant melanoma

JM Kirkwood;SS Agarwala;J Ibrahim;J Manola;VK Sondak;MS Ernstoff;MK Ross Journal of Clinical Oncology 20(8):2209-2210

2001

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of Intergroup trial E1694/S9512/C509801

JM Kirkwood;JG Ibrahim;JA Sosman;VK Sondak;SS Agarwala;MS Ernstoff;U Rao Journal of Clinical Oncology 19(9):2370-2380

2000

Overview of the role of high-dose IFN (2b(HDI) in the therapy of high-risk resectable melanoma.

JM Kirkwood;JA Sosman;MS Ernstoff;MA Ross;SS Aggarawal;HF Edington Journal of Immunotherapy 23(5):595

1997

Adjuvant therapy for melanoma.

VK Sondak;JA Wolfe Current Opinion in Oncology 9:189-204

Other Clinical Trials

SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
100%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase